Johnson & Johnson $JNJ Shares Sold by Bill Few Associates Inc.

Bill Few Associates Inc. cut its position in Johnson & Johnson (NYSE:JNJ) by 1.7% in the second quarter, HoldingsChannel reports. The institutional investor owned 9,081 shares of the company’s stock after selling 154 shares during the period. Bill Few Associates Inc.’s holdings in Johnson & Johnson were worth $1,387,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Nuveen LLC purchased a new position in Johnson & Johnson in the first quarter valued at $1,369,188,000. Bank of New York Mellon Corp boosted its holdings in Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares during the period. Pacer Advisors Inc. boosted its holdings in Johnson & Johnson by 1,382.0% in the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock valued at $502,509,000 after purchasing an additional 2,825,626 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Johnson & Johnson by 159.6% in the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after purchasing an additional 2,557,388 shares during the period. Finally, Kingstone Capital Partners Texas LLC purchased a new position in Johnson & Johnson in the second quarter valued at $401,420,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Bank of America lifted their target price on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Weiss Ratings upgraded Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. UBS Group lifted their price target on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, HSBC lifted their price target on Johnson & Johnson from $188.00 to $210.00 in a report on Tuesday, September 30th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $193.88.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.0%

Johnson & Johnson stock opened at $190.88 on Wednesday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a market capitalization of $459.70 billion, a P/E ratio of 20.41, a PEG ratio of 2.40 and a beta of 0.40. The stock has a 50-day simple moving average of $179.28 and a 200-day simple moving average of $164.16.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $24.02 billion during the quarter. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.